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ABSTRACT
Angiotensin-converting enzyme (ACE) inhibitors appear to correct many of the abnormalities
associated with the vascular dysfunction found in diabetic patients. In this respect, quinapril is a
unique ACE inhibitor with multiple protective effects. The present study was carried out to investigate
the effect of intraperitoneal administration of quinapril on the aortic reactivity of streptozotocin
(STZ)-diabetic rats. For this purpose, male Wistar rats received one injection of streptozotocin (STZ),
60 mg/kg, to induce diabetes. Three days after STZ injection, rats were treated with quinapril (2
mg/kg/day) for 4 weeks, after that aortic reactivity to vasoactive agents were compared with those of
untreated diabetic rats or non-diabetic control rats. For this purpose, contractile response to
phenylephrine (PE) was obtained from aortic rings. Concentration-response curves from quinapril-
treated diabetic rats to PE in the presence and absence of endothelium were attenuated as compared
to vehicle-treated diabetics. Therefore, the 4-week treatment of diabetic rats with quinapril could
prevent the functional changes in vascular reactivity in diabetic rats. Iran. Biomed. J. 7 (4): 173-177, 2003
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INTRODUCTION
he incidence of diabetes and its
complications is increasing to staggering
proportions [1]. Diabetes mellitus (DM) has
been identified as a primary risk factor for
cardiovascular disorders [2] and alters the vascular
responsiveness to several vasoconstrictors and
vasodilators [3]. For patients with DM,
cardiovascular abnormalities encompass macro-
vascular diseases, with heart attacks, strokes, and
gangrene; and microvascular disease, with
retinopathy, nephropathy, and neuropathy (somatic
and autonomic). Diabetic arteriopathy, which
encompasses endothelial dysfunction,
inflammation, hypercoagulability, changes in blood
flow, and platelet abnormalities, contributes to the
early evolution of other threatening complications.  
Efforts are under way to determine interventions
that may have the potential to prevent or halt the
devastating complications of DM [4]. Strategies that
interrupt the renin-angiotensin system, especially
those capable of inhibiting angiotensin-converting
enzyme (ACE) reduce cardiovascular disease
mortality and morbidity in high-risk persons such as
those with DM [5]. The usefulness of treatment
with an angiotensin-converting enzyme-inhibitor
(ACE-inhibitor) in normotensive patients with type
1 diabetes is still controversial [6]. The mechanisms
underlying pharmacological effects of ACE
inhibitors are not fully understood. Various
experimental evidences support the involvement of
hemodynamic effects and/or the stimulation of
cytoprotective prostaglandins [7]. The enhancement
of bradykinin-induced relaxation, augmented
release of endothelium-derived nitric oxide,
decreased production of endothelin-I and a free
radical scavenging action have also been postulated
[8]. Other findings confirm the role of oxidative
stress in the development of nephropathy already at
the early stages of diabetes development and point
to the possible antioxidative and nephroprotective
action of ACE inhibitors [9].
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Quinapril is a non-sulfhydryl ACE inhibitor that
has been studied extensively in a variety of in vitro
and in vivo animal models. Quinapril inhibits the
contractile and pressor effects of angiotensin I in
rabbit aorta and in rats, respectively, and lowers
blood pressure in both high- and normal-renin
rodent and diuretic-treated dog models of
hypertension [10]. Quinapril treatment in elderly
patients was efficacious and well tolerated, and
quinapril appears to be an effective antihypertensive
drug devoid of untoward effects on metabolic risk
factors for cardiovascular disease [11]. Quinapril
also produces favorable hemodynamic changes, and
improves ventricular and endothelial function in
patients with various cardiovascular disorders; these
effects are mediated through the binding of
quinapril to both tissue and plasma ACE [12].  
Although ACE inhibitors like quinapril have been
shown to enhance conduit artery endothelial
function in animal experiments and in patients with
established coronary atherosclerosis, their precise
effect in insulin-dependent diabetes mellitus has not
been well known and their efficacy is still
controversial [13]. Therefore, the present study was
carried out to investigate the effect of a 4-week
administration of quinapril on the aortic contractile
response of streptozotocin (STZ)-diabetic rats.
MATERIALS AND METHODS
Animals.  Male albino Wistar rats (the Pasteur
institute of Iran, Tehran), weighing 210-250 g (7-9
weeks old) were housed in an air-conditioned
colony room on a light/dark cycle at 21 ± 3°C and
supplied with standard pellet diet and tap water ad
libitum. The animals were randomly divided into
four experimental groups; i.e. control (VC, n = 7)
receiving 0.9% saline, quinapril-treated control
(QC, n = 7), saline-treated diabetic (VD, n = 7), and
quinapril-treated diabetic (QD, n = 7). Diabetes was
induced by a single intraperitoneal injection of STZ
(60 mg/kg) dissolved in cold 0.9% saline
immediately before use. Quinapril was administered
from day +3 thereafter at a dose of 2 mg/kg. All of
the experimental groups received the treatments
daily and intraperitoneally for a period of 4 weeks.
Serum glucose level and body weight were
monitored at the start and end of the experiment.
Diabetes was verified by a serum glucose level
higher than 250 mg/dl [14] using glucose oxidation
method (glucose oxidase kit, Zistchimie, Tehran,
Iran).
Experimental protocol.  At the end of the
experiment, the rats were anesthetized with diethyl
ether, decapitated, and after opening the abdomen,
descending thoracic aorta was carefully excised and
placed in a Petri dish filled with cold Krebs solution
containing (in mM): NaCl 118.5, KCl 4.74, CaCl2
2.5, MgSO4 1.18, KH2PO4 1.18, NaHCO3 24.9, and
glucose 10.0. The aorta was cleaned of excess
connective tissue and fat and cut into rings of
approximately 4 mm in length. One ring of each
pair was left intact, and in the other ring,
endothelium was mechanically removed by gently
rotating it on a glass rod. Aortic rings were
suspended between the bases of two triangular-
shaped wires. One wire was attached to a fixed
tissue support in a 50 ml isolated tissue bath
containing Krebs solution (pH 7.4) maintained at
37°C and continuously aerated with a mixture of
5% CO2 and 95% O2. The other end of each wire
was attached by a cotton thread to a F60 isometric
force transducer connected to MK-IV-P
physiograph (Narco Biosystems, USA). In all
experiments, special care was taken to avoid
damaging the luminal surface of endothelium. The
rings were allowed to equilibrate for 90 min under a
resting tension of 2 g before experiments were
begun. This had been shown in preliminary
experiments to be the optimal resting tension for all
groups. During equilibration period, the rings were
washed every 30 min.
At the end of the equilibration period, dose-
response curves were obtained with phenylephrine
(PE) in aortic rings. PE was added in a cumulative
manner until a maximum response was achieved.
After the addition of each dose, a plateau response
was obtained before addition of a subsequent dose.
Consecutive concentration-response curves were
taken at 30-min intervals, during which the Krebs
solution was changed at least 3 times. After each
experiment, aortic rings were blotted, weighed, and
the cross-sectional area (csa) was calculated using
the following formula: Cross-sectional area (mm2) =
weight (mg) × [length (mm) × density (mg/mm3)]-1.
The density of the preparations was assumed to be
1.05 mg/mm2 [14]. The mean weight of the blotted
aortic rings was recorded as 10.4 mg for control and
as 9.8 mg for diabetic rats.
Drugs and chemicals.  Phenylephrine-HCl and
STZ were purchased from Sigma Chemical (St.
Louis, Mo., USA). All other chemicals were
purchased from Merck (Germany).  All drugs
except STZ were dissolved in Krebs’ solution. STZ
was freshly dissolved in 0.9% saline solution.   
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Table 1.  Body weight, serum glucose level, and aortic cross-sectional area of control, diabetic, and quinapril-treated diabetic rats.   
Body weight (g) Serum glucose (mg/dl)
Week 0 Week +4 Week 0 Week +4 Cross-sectional area (mm
2)
Control
VC
QC*
213.0 ± 6.7
207.8 ± 6.3*
242.6 ± 5.2
254.3*± 5.2
107.4 ± 5.9
109.2 ± 4.2*
110.8 ± 5.1
114.3 ± 4.8*
0.99 ± 0.02
0.98 ±  0.02*
Diabetic
VD
QD*
217.2 ± 5.1
218.6 ± 7.1**
174.3 ± 3.9*
187.7 ± 4.6*
99.7 ± 4.8*
103.5 ± 5.3*
371.2 ± 13.2*
358.5 ± 11.8*
0.84 ± 0.02***
0.92 ± 0.02  *
  Data are represented as mean ± SEM. *P<0.001 (Compared to VC); **P<0.05 (Compared to VC).
Data and statistical analysis.  All values were
given as mean ± SEM. Contractile response to PE
was expressed as grams of tension per cross-
sectional area of tissue. Statistical analysis was
carried out using student’s paired t-test and one-way
analysis of variance (ANOVA) followed by Tukey
post-hoc test. Statistical P<0.05 was considered
significant.
RESULTS
Body weight, Serum glucose, and cross-sectional
area.  No marked alteration in body weight or food
or water intake was observed following 4-week
administration of quinapril (2 mg/kg/day) in QC
group compared to VC group. Body weight, serum
glucose level, and cross-sectional area of the aorta
have been shown in Table 1. After 4 weeks, the
weight of the vehicle-treated diabetic rats was found
to be significantly decreased compared to control
rats (P<0.001). Untreated diabetic rats had also an
elevated serum glucose level over those of control
rats (P<0.001). Treatment of diabetic rats with
quinapril did not cause any significant change in the
above parameters. Furthermore, a significant
reduction (P<0.05) in cross-sectional area of aortic
rings of VD group was noted in comparison with
VC group, showing the slow development of some
structural changes in the wall of vascular system
following diabetes induction.
 
Vascular reactivity. Cumulative addition of PE
(10-9-10-4 M) to the isolated organ bath resulted in
concentration-dependent contractions in aortas of
all groups (Fig. 1). The contractile responses to PE
at concentrations higher than 10-7 M in the aortas
from vehicle-treated diabetic rats in the presence
and absence of endothelium were found to be
significantly (P<0.001) greater than vehicle-treated
control rats. Furthermore, concentration-response
curves of aortas from quinapril-treated diabetic rats
to PE were attenuated compared to vehicle-treated  
diabetics, especially at concentrations greater than
10-6 for endothelium-intact rings and their responses
were  closer  to  those   of   vehicle-treated  controls.
In addition, aortic rings with intact endothelium
from quinapril-treated control group showed a
significant decrease (P<0.05) in contractile response
to PE only at concentrations higher than 10-5 when
compared to vehicle-treated control.
Fig. 1. Cumulative concentration-response curves for
phenylephrine in aortic preparations four weeks after
experiment in the presence (A) and absence (B) of endothelium.
Contractile responses are expressed as grams of tension per
cross sectional area (mm2). Data are shown as means ± SEM.
*P<0.05, ** P<0.01  (Compared to VD)(VC, QC, VD, and QD
stand for vehicle-treated control, quinapril-treated control,
vehicle-treated diabetic, and quinapril-treated diabetic,
respectively).
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DISCUSSION
 
The objective of the present study was to
investigate the beneficial effect of 4-week
administration of quinapril on the aortic reactivity
of STZ-diabetic rats. The results of the present
study demonstrated that aortas from 4-week STZ-
diabetic rats are more responsive to the contractile
effect of α1-adrenoceptor agonist like PE both in the
presence and absence of endothelium than those
from corresponding controls. Although the actual
responsible mechanisms have not been completely
understood, some possible factors that could have
been involved in the increased vascular smooth
muscle responsiveness to α1-adrenoceptor agonist
in diabetic rats are as follows: 1) deficient
endothelial activity; 2) enhanced phosphoinositide,
(PI) metabolism; 3) enhanced sensitivity of calcium
channels; 4) increased sensitivity to adrenergic
agonists; and 5) enhanced oxidative stress due to
excessive production of oxygen-free radicals and
decreased antioxidant defense systems. Therefore,
the oxidative stress in diabetic animals might be
responsible for augmented  ontractility  ogether
with deficient endothelial activity [15, 16].
The results also showed that daily i.p.
administration of quinapril for 4 weeks could
partially attenuate the increased responsiveness of
aortic rings to the vasoconstrictor agent PE,
especially in endothelium-intact rings. The
beneficial effect of sub-chronic quinapril treatment
on contractile responses was not limited to aortas of
diabetic rats, because quinapril-treated control rats
also showed a significant lower contractile response
to PE as compared to VC group. Although ACE
inhibitors are commonly used in clinical practice for
the treatment of some cardiovascular abnormalities,
but the mechanisms mediating their beneficial
effects are not clear [17].  
Several likely mechanisms could explain the
protective effect of quinapril on the functional
abnormalities observed in the diabetic rat aorta. The
results of previous studies have shown that acute in
vitro administration of quinapril could decrease
vascular responsiveness to alpha-adrenergic agonist,
possibly as a result of decreased degradation of the
bradykinin. In addition, chronic treatment of
normotensive rats with ACE inhibitors is reported
to attenuate significantly contractile responses to
both norepinephrine and phenylephrine [18]. It has
also been shown that ACE inhibitors potentiate the
effects of bradykinin on endothelial cells by a local
mechanism, probably independent of the
degradation of bradykinin [17]. Other findings
reported that the effect of ACE inhibitors is not only
via inhibition of the formation of vasoconstrictory
angiotensin II, but also by accumulation of
bradykinin that stimulates the synthesis of
vasodilatory nitric oxide (NO). In this respect, ACE
inhibitors could not alter NO synthesis by vascular
smooth muscle cells under basal and interleukin-1
beta-stimulated conditions in cultured rat vascular
smooth muscle cells [19]. The other explanation is
that ACE inhibitors have shown a free radical
scavenging action and may lower lipid peroxidation
in vascular system. Thus, since diabetes mellitus
itself is a state of increased free radical activity,
antioxidant activity of quinapril and its lipid-
peroxidation-lowering effect could exert reversal
effect on the contractility of rat aorta [20]. It is also
possible that ACE inhibitors like quinapril can
directly affect Ca2+ handling in aortic smooth
muscle cells [21]. In addition, these compounds
may also reduce the vascular expression of
plasminogen activator inhibitor-1 (PAI-1), an
important regulator of fibrinolysis and extracellular
matrix turnover vascular PAI-1 expression [22].
Taken together, this is the first study to report that
treatment of diabetic rats with quinapril could
prevent the functional changes in vascular reactivity
observed in diabetic rats. Therefore, it is suggested
that ACE inhibitors like quinapril in addition to
standardized hypoglycemic agents may be
administered as a beneficial therapeutic regimen for
diabetic patients.
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